Tectonic Therapeutic Q1 net loss widens on higher R&D costs

Tectonic Therapeutic

07/05/2026 21:26

Overview

US biotech firm's Q1 net loss widened yr/yr on higher R&D and admin expenses

Company advanced TX45 and TX2100 clinical trials, with key readouts expected in late 2026

Cash and equivalents fell to $236.9 mln, expected to fund operations into Q4 2028

Outlook

Company expects TX2100 Phase 1a topline results by end of Q3 2026

Tectonic anticipates TX45 APEX Phase 2 topline data in late Q4 2026 or early Q1 2027

Company expects current cash to provide runway into Q4 2028

Result Drivers

HIGHER R&D SPENDING - Increased research and development expenses driven by ongoing Phase 2 trial of TX45 and initiation of TX2100 clinical trial

PIPELINE ADVANCEMENT - Initiation and advancement of TX45 and TX2100 clinical trials contributed to higher operating expenses

Company press release: ID:nGNX4Kgkmq

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$25.24 mln
Q1 Basic EPS
-$1.34
Q1 Income From Operations
-$27.30 mln
Q1 Operating Expenses
$27.30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Tectonic Therapeutic Inc is $76.00, about 161.9% above its May 6 closing price of $29.02

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)